Tailored Immunonutrition Solutions for High-Risk Environments
Legal Citation
Summary of the Inventive Concept
This inventive concept adapts immunonutrition supplements for specific, high-risk environments, such as high-security isolation units, disaster relief zones, extreme weather conditions, remote off-grid locations, and pandemic quarantine zones, ensuring effective treatment or prevention of surgery-induced cachexia and related complications.
Background and Problem Solved
The original patent disclosed compositions and methods for treating or preventing surgery-induced cachexia and related complications. However, these solutions may not be suitable for high-risk environments, where specialized requirements, such as tamper-evident packaging, portability, thermal stability, satellite-enabled dispensing, and enhanced biosecurity features, are essential. This inventive concept addresses these limitations by providing tailored immunonutrition solutions for these niche environments.
Detailed Description of the Inventive Concept
The inventive concept encompasses four primary embodiments: (1) a system for high-security isolation units, featuring tamper-evident packaging; (2) a portable, self-contained immunonutrition supplement kit for disaster relief zones; (3) a composition with a thermally-stable L-arginine formulation for extreme cold weather environments; and (4) a system utilizing a satellite-enabled, automated dispensing device for remote, off-grid locations. Additionally, the inventive concept includes a method for treating or preventing cachexia induced by a pandemic, incorporating enhanced biosecurity features in the immunonutrition supplement.
Novelty and Inventive Step
The novelty of this inventive concept lies in its adaptation of immunonutrition supplements for specific, high-risk environments, addressing the unique challenges and requirements of these niches. The inventive step resides in the combination of specialized features, such as tamper-evident packaging, portability, thermal stability, satellite-enabled dispensing, and enhanced biosecurity features, which are not obvious from the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include adaptations for other high-risk environments, such as space exploration or military operations. Variations may also involve different formulations or dosages of the immunonutrition supplements, tailored to specific patient populations or medical conditions.
Potential Commercial Applications and Market
This inventive concept has significant commercial potential in the healthcare and pharmaceutical industries, particularly in the areas of critical care, emergency medicine, and disaster response. The target market includes hospitals, disaster relief organizations, and government agencies, as well as pharmaceutical companies and medical device manufacturers.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical nutrition, specifically immunonutrition and cachexia treatment, with expertise in pharmaceutical formulation, patient-specific nutritional interventions, and medical supplement design
Person of Ordinary Skill (PHOSITA) Profile
A medical nutritionist or pharmaceutical researcher with advanced degrees in nutrition science, clinical pharmacology, or related biomedical fields, possessing knowledge of specialized nutritional supplements, patient-specific treatment strategies, and formulation techniques
Obviousness Rationale
A PHOSITA would recognize that the PTD represents predictable extensions of the source patent's core immunonutrition supplement concept by adapting the fundamental composition to specific environmental and logistical challenges. The variations demonstrate standard engineering problem-solving approaches that apply known nutritional supplement principles to unique delivery contexts. The PTD's modifications represent routine adaptations that would be immediately apparent to a skilled practitioner seeking to expand the original patent's therapeutic applications.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,525 |
|---|---|
| Title | Treatment or prevention of surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines |
| Assignee(s) | SOCIÉTÉ DES PRODUITS NESTLÉ S.A. |